- Home
- DSGN vs AMRN Comparison
DSGN vs AMRN Comparison
Compare DSGN & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSGN
- AMRN
- Stock Information
- Founded
- DSGN 2017
- AMRN 1989
- Country
- DSGN United States
- AMRN Ireland
- Employees
- DSGN N/A
- AMRN N/A
- Industry
- DSGN Biotechnology: Pharmaceutical Preparations
- AMRN Biotechnology: Pharmaceutical Preparations
- Sector
- DSGN Health Care
- AMRN Health Care
- Exchange
- DSGN Nasdaq
- AMRN Nasdaq
- Market Cap
- DSGN 208.9M
- AMRN 216.0M
- IPO Year
- DSGN 2021
- AMRN 1993
- Fundamental
- Price
- DSGN $5.26
- AMRN $15.98
- Analyst Decision
- DSGN
- AMRN Strong Sell
- Analyst Count
- DSGN 0
- AMRN 1
- Target Price
- DSGN N/A
- AMRN $12.00
- AVG Volume (30 Days)
- DSGN 141.5K
- AMRN 69.5K
- Earning Date
- DSGN 08-07-2025
- AMRN 07-30-2025
- Dividend Yield
- DSGN N/A
- AMRN N/A
- EPS Growth
- DSGN N/A
- AMRN N/A
- EPS
- DSGN N/A
- AMRN N/A
- Revenue
- DSGN N/A
- AMRN $219,361,000.00
- Revenue This Year
- DSGN N/A
- AMRN N/A
- Revenue Next Year
- DSGN N/A
- AMRN N/A
- P/E Ratio
- DSGN N/A
- AMRN N/A
- Revenue Growth
- DSGN N/A
- AMRN N/A
- 52 Week Low
- DSGN $2.60
- AMRN $7.08
- 52 Week High
- DSGN $7.77
- AMRN $17.49
- Technical
- Relative Strength Index (RSI)
- DSGN 61.90
- AMRN 59.78
- Support Level
- DSGN $4.68
- AMRN $15.54
- Resistance Level
- DSGN $5.60
- AMRN $16.50
- Average True Range (ATR)
- DSGN 0.39
- AMRN 0.48
- MACD
- DSGN 0.04
- AMRN 0.08
- Stochastic Oscillator
- DSGN 79.95
- AMRN 73.06
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.
About AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.